Financial Survey: Pacira BioSciences (NASDAQ:PCRX) & Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Pacira BioSciences (NASDAQ:PCRX) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares Pacira BioSciences and Kiniksa Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pacira BioSciences $421.03 million 5.21 -$11.02 million $0.86 58.69
Kiniksa Pharmaceuticals N/A N/A -$161.87 million ($2.99) -5.10

Pacira BioSciences has higher revenue and earnings than Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Pacira BioSciences and Kiniksa Pharmaceuticals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacira BioSciences 0 2 10 0 2.83
Kiniksa Pharmaceuticals 0 0 3 0 3.00

Pacira BioSciences presently has a consensus target price of $64.67, suggesting a potential upside of 28.13%. Kiniksa Pharmaceuticals has a consensus target price of $33.75, suggesting a potential upside of 121.31%. Given Kiniksa Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Pacira BioSciences.

Institutional and Insider Ownership

31.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 5.8% of Pacira BioSciences shares are owned by company insiders. Comparatively, 70.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Pacira BioSciences has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of -0.13, meaning that its stock price is 113% less volatile than the S&P 500.


This table compares Pacira BioSciences and Kiniksa Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pacira BioSciences -2.47% 10.27% 4.52%
Kiniksa Pharmaceuticals N/A -52.59% -47.49%


Pacira BioSciences beats Kiniksa Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor; and KPL-045, a monoclonal antibody inhibitor of the CD30 ligand co-stimulatory molecule. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with's FREE daily email newsletter.